説明

A study by StrategyHelix indicates that the global clinical next-generation sequencing market is expected to increase by US$ 18.4 10億から 2022 に 2028, のCAGRを獲得 23.4% 予測期間中.

レポートは、期間の最新の市場規模データを提供します。 2018-2021 そして次のように予測します 2028 covering key market aspects like sales value for clinical next-generation sequencing. The global clinical next-generation sequencing market is segmented on the basis of component, disease class, disease category, test complexity, test purpose, と地域. コンポーネントに基づく, the global clinical next-generation sequencing market is categorized into instrument, workflow solution (kits, サービス, 等). On the basis of disease class, the global clinical next-generation sequencing market has been segmented into cancer, non-cancer. The non-cancer segment captured the largest share of the market in 2021. By disease category, the global clinical next-generation sequencing market has been segmented into cardiovascular, clinical microbiology and infectious diseases, mendelian disorders, metabolic/immune, neurological, oncology, reproductive health, transplantation. 研究によると, the oncology segment had the largest share in the global clinical next-generation sequencing market. Based upon test complexity, the global clinical next-generation sequencing market is categorized into hotspot, multi-gene, single gene, whole genome, whole/targeted exome. The multi-gene segment held the largest revenue share in 2021. On the basis of test purpose, the global clinical next-generation sequencing market has been segmented into diagnosis, monitoring, screening/early detection, therapy guidance. 地理的には, the global clinical next-generation sequencing market has been segmented into Asia Pacific, ヨーロッパ, 北米, 世界のその他の地域 (行).

The global clinical next-generation sequencing market is highly competitive. 現在 2021, the major players in the global clinical next-generation sequencing market were ANGLE plc, Becton Dickinson and Company, BGI Group, Biocept Inc., Biodesix Inc., Biolidics Limited, Bio-Techne Corporation, Burning Rock Biotech Limited, CareDx Inc., Danaher Corp., Epigenomics AG, Eurofins Scientific SE, EXACT Sciences Corporation, Fulgent Genetics Inc., GeneDx Inc., Guardant Health Inc., Illumina Inc., コニンクライケ フィリップス N.V., Merck KGaA, Myriad Genetics Inc., NeoGenomics Laboratories Inc., Qiagen N.V., Quest Diagnostics Incorporated, ロシュ・ホールディングAG, Thermo Fisher Scientific Inc.

このレポートは、この業界で活動する企業や組織にとって非常に貴重なリソースです。. It provides a cohesive picture of the clinical next-generation sequencing market to help drive informed decision making for industry executives, 政策立案者, アカデミック, とアナリスト.

レポートの範囲

成分: instrument, workflow solution (kits, サービス, 等)
Disease class: cancer, non-cancer
Disease category: cardiovascular, clinical microbiology and infectious diseases, mendelian disorders, metabolic/immune, neurological, oncology, reproductive health, transplantation
Test complexity: hotspot, multi-gene, single gene, whole genome, whole/targeted exome
Test purpose: diagnosis, monitoring, screening/early detection, therapy guidance
領域: アジア太平洋地域, ヨーロッパ, 北米, 世界のその他の地域 (行)
考慮した年数: このレポートはその期間をカバーしています 2018 に 2028

関係者にとっての主なメリット

– Get a comprehensive picture of the global clinical next-generation sequencing market
– 地域データに基づいて地域戦略と戦略的優先事項を特定する
– 成長セクターと投資トレンドを正確に特定する

目次

部 1. 序章
– 研究の範囲
– 勉強期間
– 地理的範囲
– 研究方法
部 2. Clinical next-generation sequencing market overview
部 3. コンポーネント別の市場内訳
– Instrument
– Workflow solution (kits, サービス, 等)
部 4. Market breakdown by disease class
– Cancer
– Non-cancer
部 5. Market breakdown by disease category
– Cardiovascular
– Clinical microbiology and infectious diseases
– Mendelian disorders
– Metabolic/immune
– Neurological
– Oncology
– Reproductive health
– Transplantation
部 6. Market breakdown by test complexity
– Hotspot
– Multi-gene
– Single gene
– Whole genome
– Whole/targeted exome
部 7. Market breakdown by test purpose
– Diagnosis
– Monitoring
– Screening/early detection
– Therapy guidance
部 8. 地域ごとの市場の内訳
– アジア太平洋地域
– ヨーロッパ
– 北米
– 世界のその他の地域 (行)
部 9. 主要企業
– ANGLE plc
– ベクトン, Dickinson and Company
– BGI Group
– Biocept, 株式会社.
– Biodesix, 株式会社.
– Biolidics Limited
– Bio-Techne Corporation
– Burning Rock Biotech Limited
– CareDx, 株式会社.
– Danaher Corp.
– Epigenomics AG
– Eurofins Scientific SE
– EXACT Sciences Corporation
– Fulgent Genetics Inc.
– GeneDx Inc.
– Guardant Health, 株式会社.
– Illumina, 株式会社.
– Koninklijke Philips N.V..
– Merck KGaA
– Myriad Genetics, 株式会社.
– NeoGenomics Laboratories, 株式会社.
– Qiagen N.V.
– Quest Diagnostics Incorporated
– ロシュ・ホールディングAG
– Thermo Fisher Scientific Inc.
StrategyHelix について
免責事項